TD Asset Management Inc Has $11.80 Million Position in Guardant Health, Inc. $GH

TD Asset Management Inc lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 16.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 188,810 shares of the company’s stock after buying an additional 26,210 shares during the quarter. TD Asset Management Inc’s holdings in Guardant Health were worth $11,797,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC increased its holdings in Guardant Health by 56.5% in the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock valued at $3,012,000 after buying an additional 25,831 shares during the period. Empowered Funds LLC acquired a new position in Guardant Health during the 1st quarter worth approximately $274,000. Envestnet Asset Management Inc. increased its position in Guardant Health by 40.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 38,622 shares of the company’s stock worth $2,010,000 after purchasing an additional 11,125 shares in the last quarter. Atria Investments Inc bought a new position in Guardant Health in the 2nd quarter valued at approximately $209,000. Finally, Strs Ohio boosted its position in Guardant Health by 7.4% in the second quarter. Strs Ohio now owns 20,400 shares of the company’s stock valued at $1,062,000 after buying an additional 1,400 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on GH shares. Evercore set a $110.00 price target on shares of Guardant Health in a report on Friday, February 20th. BTIG Research boosted their price objective on Guardant Health from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. UBS Group reaffirmed a “buy” rating and issued a $175.00 target price on shares of Guardant Health in a report on Friday, January 30th. Morgan Stanley lifted their price target on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Finally, Citigroup boosted their price target on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Twenty-one analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $122.57.

Guardant Health Trading Down 4.2%

NASDAQ GH opened at $93.90 on Monday. The firm has a market capitalization of $12.32 billion, a PE ratio of -28.37 and a beta of 1.67. The business’s 50-day moving average price is $106.29 and its two-hundred day moving average price is $87.95. Guardant Health, Inc. has a 12 month low of $34.88 and a 12 month high of $120.74.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. During the same quarter in the prior year, the company posted ($0.62) earnings per share. Guardant Health’s revenue for the quarter was up 39.4% compared to the same quarter last year. As a group, analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Activity at Guardant Health

In related news, CTO Darya Chudova sold 5,451 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $104.04, for a total transaction of $567,122.04. Following the transaction, the chief technology officer owned 7,012 shares in the company, valued at $729,528.48. The trade was a 43.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terilyn J. Monroe sold 8,571 shares of the business’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the completion of the sale, the insider directly owned 20,990 shares of the company’s stock, valued at $2,394,749.10. The trade was a 28.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 379,344 shares of company stock valued at $39,734,840 over the last 90 days. 6.10% of the stock is owned by company insiders.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.